Manar Almoneef

Manar Almoneef

Chief Operating Officer, International Government affairs and policy leader

  • Saudi Arabia .

Summary

Proactive, proformance-driven professional with 15 years of experience leading Market Development Initiative in Government and Corporate enviroment. Deep helathcare and life science expertise, Result oriented, decisive leader, with proven success record in establishing new business, identifying growth opportunities, and initiating strong business alliances. Thrive in dynamically changing environments requiring focused decision making. Skilled in optimizing teams dynamics, uniting diverse agenda to a common goal, and harnessing strategic and operational drivers to deliver results.

Value offered

Enterprising visionary

Strategic alliances

Cross functional relationship building

Operational, service delivery and project management

business development skills

Technology and business solutions

Enterprise, corporate and SME client management

Sales, marketing analysis

 

Work History

Work History

Chief Operating Officer,  Marketing Executive

GE oil and Gas
Jan 2015 - Present

Develop the Growth Strategy for DTS and Distributed gas solution market to generate double digit growth globally with specific focus on the MENAT. Build a strong pipeline of projects and initiatives to position GE as an industry  and solution provider.  Develop strategic initiative with customer to support the business growth and increase market share.

Chief Operating Officer (COO)

GE
Jan 2014 - Dec 2014

Lead the commercial and operational strategy for GE by creating and executing on growth plans; identifying and developing new business opportunities; building capacity and capability; and building relationships with key customers and the government.

Director of Government Affairs and policy

GE
Sep 2012 - Jan 2014

Responsible for leading the company strategy in the region by aligning the company development with the region needs. Build GE’s relationship with governments across all business’s, advise GE across businesses on policy and regulatory issues and develop of new “white space” business opportunities for GE in the region.

Managing Director, Imagination Breakthrough

GE healthcare
Sep 2011 - Sep 2012

Responsible for leading the business development efforts for GE health care within the Middle East region, focusing on recognizing and building opportunities to drive organic growth for GE business in the region. Provide strategic and technical consulting for launching new applications and products in the emerging markets and taking them global. Integrated member of a large team at GE that is dedicated to solve tough global problems for customers and society.

Imagination Breakthrough (IB) is a new business segment within GE that was created in May 2009 with a $3 billion budget to invest in emerging market and develop pioneering health care innovations and take them globally. GE is an innovative advanced technology, infrastructure and financial service company that operate in more than 100 countries and employee about 300,000 people worldwide.

Director General, Health Care and Life Sciences

Saudi Arabian general investment authority, SAGIA
Sep 2006 - Sep 2011

Progressed from Head of life sciences to an increasingly responsible position as the Director General of Health Care & Life Sciences, providing strategic and technical consulting in all health care and life science business development, lead all health care and life science strategic-driven revenue models. Develop business and functional requirements. Lead all health care and life Sciences investments which include (heath care strategies, health care investments, pharmaceutical, bio-pharmaceutical, medical devices, agrochemical, agriculture, aqua-agriculture, biomass and marina life science, fine chemical production, industrial enzymes production, biotech pollution and biotech application for water treatment, renewable and alternative energy and all environmental initiatives). Develop the first life science strategy in the Middle East; with the ultimate goal of creating an advanced society, proficient in science & technology. Develop next generation of life science and health care laws and regulation covering all segments of health care & life sciences. Develop the new health care and life science strategy for the economic cities which include developing new licensing regulation, developing an e-based monitoring and evaluation system, developing the strategies for creating a pharmaceutical cluster, agrochemical cluster, a fine chemical cluster and finally a solar cluster. Create supportive regulatory framework benchmarked to international best practice and the development of unique value propositions for each segment.

Responsibilities

  • Top level health care and life sciences strategic vision, planning and business development.
  • Drafting and managing multi-million dollar budgets and business plans.
  • In charge of all health care and life science investment promotion. 

Key Achievements

  • Successfully delivered 2006-20010 business plans.
  • Spearheaded and executed a number of key agreements with government and privet sectors which include an agreement with KACST to support 50% of all R&D activities within the economic cities.
  • Successfully orchestrated the lunch of two strategies with the buy-inn from of the regulators.
  • Championed & implemented a successful Business Conduct.
  • Successfully trained, mentored and motivated health care and life science Employees.
  • Developed & implemented many successful operational/ business strategies.
  • Created numerous successful partnerships & strategies to ensure revenue goals.
  • Counseled and motivated staff to achieve all targets.
  • Consistently surpassed all personal targets within deadline & budget.

Molecular Oncologist, Department of molecular pathology and Genetics , Assistant professor, School of Medicine and allied medical since

King Saud medical study’s university, king Abdulaziz medical city, NGHA
Sep 2004 - Sep 2006

Develop the plan for all molecular testing within the National Guard health affairs, in a systematic way to include, method development, evaluation, clinical trial, validation, implementation, monitoring, benchmarking and a through follow up to all patients. Developed the work plan for the section and led the collage of American pathologist (CAP) and Joint Commission International Accreditation (JCIA) inspection with a distinction for meeting all the required standards. Create the personal development plan for all the employees, setting out their target and how to achieve it. Created an annual data base to follow-up all patients’ viral load and complications due to treatment to be reported to the consultant in charge, led the development of nucleic acid testing for blood bank donors (NAT) which included more than 4000 donors that was tested for HCV, HIV and HBV. Developed an integrated plan for all interns, residents and fellows within the department to gain knowledge of all activities, procedures, information, methodology and techniques preformed, develop an assessment tool to objectively evaluate all the staff and inters for their performance.

A contributing member to the chemistry and pathology department led the clinical chemistry, organic chemistry and biological chemistry classes within the university. Created a systematic way of linking all the chapters into one main project that will contribute significantly in the student’s progression plan and career path, this system resulted in a 100% success rate among all students.

Post doctoral fellow in the medical research council, Department of cancer studies

Medical Research Council, leicester
Sep 2003 - Sep 2004

Developed the basis of a clinical trial to evaluate the chemo sensitivity and radio sensitivity of patients prior to treatment and follow up post treatment. Contributed as an active member of the team to the success of the clinical trial and publicising the results.

Education

Education

Executive MBA

Harvard Business School
2010 - 2010

PhD

Leicester University
Oct 1999 - Sep 2003

Evaluation of The Alkaline Comet Assay as a Rapid Productive Assay of Radiotherapy and chemotherapy in Bladder Cancer

Msc. Reading Molecular Medicine

Cambridge University
Jan 1998 - Jan 1999

Bsc. Honours. Reading Medicine

KSU
Sep 1990 - Sep 1995

Training Courses

  • Leadership management
  • Advanced marketing and management
  • Public speaking course
  • Project management
  • Leaders in corporate businesses
  • High potential leadership program
  • Women network development
  • Business development course
  • Management Development Course
  • Leadership, innovation and growth

Publications

Colquhoun, A., Jones, G.D.D., Al Moneef, M., Symonds, R.P., Steward, W.P., Mellon, J.K., 2003. Improving and predicting radiosensitivity in muscle invasive bladder cancer. Journal of Urology, 169, 1983-1992.

 

Al Moneef, M., Sherwood, B.T., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2003, Measures by the alkaline comet assay predict bladder cancer cell radiosensitivity. British Journal of Cancer, 89, 2271-2276.

 

Sherwood, B.T., Jones, G.D.D., Al Moneef, M., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., and Mellon, K.J., 2007, Mechanisms of radioresistance in bladder cancer. International Radiation Oncology..

 

AL Moneef, M., Sherwood, B.T., Bowman, K.J., Kockelbergh, R.C., Symonds, R.P., Steward, W.P., Mellon, J.K. and Jones, G.D.D., Comet assay analysis of DNA substrates of bladder cancer cells.

 

AL Moneef, M., Sherwood, B.T., Bowman, K.J., Symonds, R.P., Kockelbergh, R.C., Mellon, J.K., Steward, W.P. and Jones, G.D.D., 2005, Comet assay measures of cis-platin and mitomycin C-induced DNA crosslink formation predicts bladder cancer cell chemo sensitivity

in vitro, of the American Association for Cancer Research 45, 356 (abstract 1545).

 

Al Moneef, M., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2002, Evaluation of the alkaline comet assay as a predictive test of invasive bladder cancer treatment: prediction of bladder cancer cell radiosensitivity and chemosensitivity. Proceedings of the American Association for Cancer Research 43, 400 (Abstract 1991).

 

Al Moneef, M., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2002, Radiobiology studies in bladder cancer: Evaluation of the alkaline comet assay as a predictive test of bladder cell radiosensitivity (& chemosensitivity). 2nd Institute of Cancer Studies Study day, 20th June 2002, Beamanour Hall, Leicester.

 

Al Moneef, M., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2002, Evaluation of the alkaline comet assay as a predictive test of invasive bladder cancer treatment: prediction of bladder cancer cell radiosensitivity and chemosensitivity. Mutagenesis, 17, 559 (abstract 25).

 

Sherwood, B.T., Al Moneef, M., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2003, Evaluation of the alkaline comet assay as a predictive test bladder cancer cell radiosensitivity. Urological Research Society Mtg., 10th January 2003, the Riyal College of Surgeons of England, London. BJU International, 92, 826.

 

Sherwood, B.T., Al Moneef, M., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2003, Alkaline comet assay predicts bladder cancer cell radiosensitivity. Association for Radiation Research 2003 Scientific Meting., 27th March 2003, St. Catherines College, Oxford.

 

Sherwood, B.T., Al Moneef, M., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2003, Alkaline comet formation best predict bladder cancer cell radiosensitivity. Biological Basis of Sensitivity to Ionizing Radiation International Workshop, 9th – 10th May 2003, DKFZ, Heidelberg., (European Journal of Genetic Toxicology), In press.

 

Sherwood, B.T., Al Moneef, M., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2003, The alkaline comet assay and therapy in bladder cancer, 3ed Institute of Cancer Studies Study Day, 22nd May 2003, Highpoint, Glenfield, Leicester.

 

Al Moneef, M., Sherwood, B.T., Bowman, K.J., Kockellbergh, R.C., Symonds, R.P., Stewart, W.P., Mellon, K.J., and Jones, G.D.D., 2003, Comet assay analysis of DNA cell substrates, International Comet Assay Workshop No. 5, August 29-31, University of Aberdeen Scotland.

 

AL Moneef, M., Sherwood, B.T., Bowman, K.J., Symonds, R.P., Kockelbergh, R.C., Mellon, J.K., Steward, W.P. and Jones, G.D.D., 2004, Comet assay measures of cis-platin and mitomycin C-induced DNA crosslink formation predicts bladder cancer cell chemosensitivity in vitro. Proceedings of the American Association for Cancer Research 45, 356 (abstract 1545).

 

Sherwood, B.T., AL Moneef. M., Bowman, K.J., Kockelbergh, R.C., Symonds, R.P., Steward, W.P., Mellon, J.K. and Jones, G.D.D., 2004, Alkaline comet assay analysis of bladder cancer cell radiosensitivity. Urological Research Society Mtg., 10th January 2004, the Royal College of Surgeons of England, London.

 

Sherwood, B.T., AL Moneef, M., Kockelbergh, R.C., Symonds, R.P., Steward, W.P. Mellon, J.K., and Jones, G.D.D., 2004, Can the alkaline comet assay predict outcome of radiotherapy for muscle-invasive bladder vancer? BJU International 93, 85.

 

Sherwood, B.T., Richardson, D., Colquhoun, A.J., Jones, G.D.D., O’Byrne K.J., Kockelbergh, R.C., Symonds, R.P., Steward, W.P. and Mellon, J.K., 2004, Hypoxia, Carbonic anhydrase IX and outcome after radiotherapy for muscle-invasive bladder cancer? Association of Radiation Research Annual Meeting, Great Missenden, UK, May 2004.

 

AL Moneef, M., Sherwood, B.T., Bowman, K.J., Kockelbergh, R.C., Symonds, R.P., Steward, W.P., Mellon, J.K., McKelvey-Martin, V.J., McKeown, S.R. and Jones, G.D.D., 2004, Alkaline comet assay measurements of cancer cell radiosensitivity & chemosensitivity. ‘Prognostic Testing in Cancer’ a one day meeting of the BIR’s Radiation and Cancer Biology Committee, British Institute of Radiology, 3rd November 2004, London.

 

AL-Moneef, M., Sherwood, B.T., Bowman, K.J., Kockelbergh, R.C., Symonds, R.P., Steward, W.P., Mellon, J.K. and Jones, G.D.D., 2004, Measures of cisplatin and mitomycin C-induced DNA crosslink formation, as determined by comet assay, predicts in vitro bladder cancer cell chemosensitivity. Mutagenesis, 19, 510.

 

Colquhoun AJ, Jones GD, Moneef MA, Bowman KJ, Kockelbergh RC, Symonds RP, Steward WP, Mellon JK. 2003, Improving and predicting radiosensitivity in muscle invasive bladder cancer. Journal of Urology. 169(6), 1983-92.